Seiya Ohtani

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

M. Shibata, Naoki Miyazaki, J. Nakahara, 2022, BMC Neurology.

Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study

Naoki Miyazaki, J. Nakahara, T. Takizawa, 2023, The Journal of Headache and Pain.

Migraine triggers in Asian countries: a narrative review

K. Peng, J. Nakahara, Mi Ji Lee, 2023, Frontiers in Neurology.

Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review

D. García‐Azorín, T. Takizawa, S. Uno, 2023, Expert opinion on drug metabolism & toxicology.